Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]

Current Controlled Trials in Cardiovascular Medicine

Volumn 6, Issue , 2005, Pages

  Ostadal, Petr ^a   Alan, David ^a   Hajek, Petr ^a   Vejvoda, Jiri ^a   Mates, Martin ^a   Blasko, Peter ^a   Veselka, Josef ^a   Kvapil, Milan ^a   Kettner, Jiri ^b   Wiendl, Martin ^b   Aschermann, Ondrej ^c   Slaby, Josef ^d   Nemecek, Eduard ^e   Holm, Frantisek ^f   Rac, Marek ^g   Macek, Milan ^a   Cepova, Jana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

^d Hospital Kolin   (Czech Republic)

^e Na Franti ku Hospital   (Czech Republic)

^f REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^g MARTIN FACULTY HOSPITAL   (Slovakia)

Author keywords

Acute coronary syndrome; C reactive protein; Fluvastatin; Interleukin 6; Pregnancy associated plasma protein A; Statin

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; FLUINDOSTATIN; INTERLEUKIN 6; LESCOL XL; PLACEBO; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PILOT STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; ST SEGMENT ELEVATION;

EID: 18144381852     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-6-4     Document Type: Article

References (39)

1. Whicher J, Biasucci L, Rifai N: Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999, 37(5):495-503.
2. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990, 65(5):297-302.
3. Serneri GG, Abbate K, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F, et al.: Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992, 86(3):790-797.
4. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A: Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94(3):874-877.
5. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 2001, 89(9):763-771.
6. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E: C-reactive protein is a potent predictor of mortality independentry of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31(7):1460-1465.
7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349(9050):462-466.
8. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331(7):417-424.
9. Rifai N, Ridker PM: High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001, 47(3):403-411.
10. Randomised trial of cholesterol lowering in 4444 patiens with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335(14):1001-1009.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333(20):1301-1307.
13. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98(9):839-844.
14. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AMJ: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344(26):1959-1965.
15. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000, 80(7):1095-1100.
16. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, Shimada K: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000, 36(3):325-329.
17. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001, 103(7):993-999.
18. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE: Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 2001, 88(4):431-433.
19. Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996, 18(11):669-675.
20. Ikeda U, Shimada K: Statins and monocytes. Lancet 1999, 353(9169):2070.
21. Rosenson RS, Tangney CC, Casey LC; Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353(9157):983-984.
22. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000, 36(2):427-431.
23. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of acherosclerosis. J Am Coll Cardiol 1998, 32(7):2057-2064.
24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 2001, 285(13):1711-1718.
25. Den Hartag FR, Van Kalmthout PM, Van Loenhout TT, Schaafsma HJ, Rila H, Verheugt FW: Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial. Int J Clin Pract 2001, 55(5):300-304.
26. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Voldhuisen DJ: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002, 23(24):1931-1937.
27. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, Schulthess HP: Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000, 86(12):1293-1298.
28. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495-1504.
29. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama 2004, 292(11):1307-1316.
30. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004, 148(1):e2.
31. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999, 100(2):178-184.
32. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T, Takeda H, Hori M: Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 1999, 34(7):2120-2125.
33. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, Lefer AM: HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. Faseb J 2001, 15(8):1454-1456.
34. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A, De Caterina R: Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001, 51(2):283-293.
35. Hayashidani S, Tsutsui, H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105(7):868-873.
36. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105(12):1446-1452.
37. Walter DH, Fichtlscherer S, Britten MB, Auch-Schwelk W, Schachinger V, Zeiher AM: Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002, 89(1):1-6.
38. Bybee KA, Wright RS, Williams BA, Murphy JG, Holmes DRJ, Kopecky SL: Effect of concomitant or very early statin adiministration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001, 87(6):771-4, A7.
39. Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, Mates M, Vojacek J: The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem 2003, 246(1-2):45-50.